Skip to main navigation

Fate Therapeutics

0
Skip to content
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Immuno-Oncology Candidates
      • FT500
      • FT516
      • FT596
      • FT538
      • FT576
      • FT819
    • Immuno-Regulation Candidates
      • ProTmune™
      • FT301
  • Science
    • Ex Vivo Cell Modulation
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Join Our Team
    • Career Opportunities
    • Vision, Mission, Values
    • Working at Fate
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historic Stock Lookup
    • Investors FAQs
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
    • Investors FAQs

Financials & Filings

ANNUAL REPORTS

Title View
2019 Annual Report 1.1 MB
2019 Annual Report 1.1 MB
2018 Annual Report 9.6 MB
2018 Annual Report 9.6 MB

PROXY STATEMENTS

Filing date View
Mar 20, 2020 View HTML
0001193125-20-080634.pdf
0001193125-20-080634.xls
Apr 08, 2019 View HTML
0001193125-19-100680.pdf
0001193125-19-100680.xls

FORM 10-K

Filing date View
Feb 24, 2021 View HTML
0001564590-21-008086.pdf
0001564590-21-008086.xls
Mar 02, 2020 View HTML
0001564590-20-008141.pdf
0001564590-20-008141.xls

FORM 10-Q

Filing date View
Nov 05, 2020 View HTML
0001564590-20-051301.pdf
0001564590-20-051301.xls
Aug 05, 2020 View HTML
0001564590-20-036806.pdf
0001564590-20-036806.xls

Shareholder Tools

Printed Materials
Email Alerts
Download Library
RSS News Feeds
Print Page
Share
Search

  • Facebook
  • LinkedIn
  • Twitter
  • RSS

© 2021 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGAL

MENU
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Immuno-Oncology Candidates
      • FT500
      • FT516
      • FT596
      • FT538
      • FT576
      • FT819
    • Immuno-Regulation Candidates
      • ProTmune™
      • FT301
  • Science
    • Ex Vivo Cell Modulation
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Join Our Team
    • Vision, Mission, Values
    • Working at Fate
    • Career Opportunities
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historic Stock Lookup
    • Investors FAQs
  • Contact